Zenagamtide
unknown (auto-discovered: incretin-obesity, peptides-regenerative)
Classification
Peptide
Regulatory Status
investigational; registered trials: NCT07868354, NCT07861100, NCT07855133 (PHASE1/PHASE3)
Unofficial source
Sources
3
Review
pending review
Overview
Unknown — Zenagamtide was found by open discovery on 2026-10-26 and has not been researched yet.
Evidence and limitations
Known
n/a
Unknown
- Mechanism, dosing, safety, interactions and efficacy are unknown until research runs on this auto-discovered draft.
Study details: trial conditions, not guidance
These are the conditions researchers used in a controlled trial with medical supervision. They aren't instructions.
Doses found
Doses as found in each source, with its grade. What was found, not a direction.
Studies, trials and professional sources
n/a
Reddit, Facebook, Instagram, forums and blogs
n/a
Claims and grades
- Not gradedZenagamtide is being studied in a registered trial: A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication (NCT07868354; PHASE1; RECRUITING; sponsor Novo Nordisk A/S; intervention "Zenagamtide" (DRUG)).
- Not gradedZenagamtide is being studied in a registered trial: A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity (NCT07861100; PHASE3; NOT_YET_RECRUITING; sponsor Novo Nordisk A/S; intervention "Zenagamtide" (DRUG)).
- Not gradedZenagamtide is being studied in a registered trial: A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication (NCT07855133; PHASE1; RECRUITING; sponsor Novo Nordisk A/S; intervention "Zenagamtide" (DRUG)).
Sources (3)
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Tirzepatide Medication (opens in a new tab) · ClinicalTrials.gov · trial-registry · 2026-10-09
- A Research Study to Look at How Well Zenagamtide Works Compared to Placebo in People With Established Atherosclerotic Cardiovascular Disease and Either Overweight or Obesity (opens in a new tab) · ClinicalTrials.gov · trial-registry · 2026-10-06
- A Research Study Investigating How Adults With Overweight or Obesity, With or Without Type 2 Diabetes, Tolerate Switching to a New Treatment (Zenagamtide) From Their Current Semaglutide Medication (opens in a new tab) · ClinicalTrials.gov · trial-registry · 2026-10-02
Educational reference only — not medical advice.
What people report (anecdote)
CLINICAL DATA (from trials)
Adverse events:
None recorded in our sources.
Effects measured:
Human trials: none found.
ANECDOTE
What people report: anecdote, not evidence
Loading…
Submit a claim you saw